Catherine Ternisien

2.4k total citations
71 papers, 1.6k citations indexed

About

Catherine Ternisien is a scholar working on Hematology, Surgery and Genetics. According to data from OpenAlex, Catherine Ternisien has authored 71 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Hematology, 17 papers in Surgery and 14 papers in Genetics. Recurrent topics in Catherine Ternisien's work include Platelet Disorders and Treatments (40 papers), Hemophilia Treatment and Research (27 papers) and Blood Coagulation and Thrombosis Mechanisms (22 papers). Catherine Ternisien is often cited by papers focused on Platelet Disorders and Treatments (40 papers), Hemophilia Treatment and Research (27 papers) and Blood Coagulation and Thrombosis Mechanisms (22 papers). Catherine Ternisien collaborates with scholars based in France, United States and Canada. Catherine Ternisien's co-authors include Paul Calès, Yves Gallois, Marc Trossaërt, Anselme Konaté, I. Hubert-Fouchard, Alain Chevailler, Dominique de Prost, Marie‐Christine Rousselet, Frédéric Oberti and Véronique Ollivier and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Catherine Ternisien

66 papers receiving 1.6k citations

Peers

Countries citing papers authored by Catherine Ternisien

Since Specialization

Citations

This map shows the geographic impact of Catherine Ternisien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Ternisien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Ternisien more than expected).

Fields of papers citing papers by Catherine Ternisien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Ternisien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Ternisien. The network helps show where Catherine Ternisien may publish in the future.

Co-authorship network of co-authors of Catherine Ternisien

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Ternisien. A scholar is included among the top collaborators of Catherine Ternisien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Ternisien. Catherine Ternisien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bleeding management in type 3 von Willebrand disease with anti‐von Willebrand factor inhibitor: A literature review and case report 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Marianne Sigaud, Marc Trossaërt, (unknown), Catherine Ternisien, Marc Fouassier, (unknown)	3
2	Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures 2024 ·Haemophilia ·Dominique Desprez, (unknown), (unknown), (unknown), Laurent Sattler, Catherine Ternisien, (unknown), Marc Trossaërt, (unknown), Marc Fouassier, (unknown), Olivier Feugeas, (unknown)	1
3	Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study 2023 ·Transfusion ·(unknown), (unknown), (unknown), (unknown), Philippe Beurrier, Catherine Ternisien, (unknown), Marc Fouassier, (unknown), Marc Trossaërt	1
4	Prothrombin consumption as an indicator of hemorrhagic phenotype in mild platelet function disorders 2023 ·European Journal Of Haematology ·(unknown), Camille Debord, (unknown), Marion Eveillard, Marc Trossaërt, Catherine Ternisien, Marianne Sigaud, (unknown), Marie C. Béné, Marc Fouassier	0
5	Modèle hub & spoke en France : organisation des soins et parcours des patients pour la thérapie génique de l’hémophilie 2023 ·Hématologie ·Yesim Dargaud, Antoine Rauch, Anne Lienhart, Laurent Frenzel, Virginie Barbay, (unknown), (unknown), (unknown), Roseline d’Oiron, Brigitte Pan‐Petesch, Geneviève Piétu, (unknown), Catherine Ternisien, B. Wibaut, Hérvè Chambost	3
6	Prostate interventions in patients with mild haemophilia: Safe and feasible 2021 ·Haemophilia ·(unknown), (unknown), Marianne Sigaud, (unknown), (unknown), Catherine Ternisien, Marc Fouassier, (unknown), S. De Vergie, Marie‐Aimée Perrouin‐Verbe, J. Rigaud, (unknown), Marc Trossaërt, Julien Branchereau	3
7	Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals) 2020 ·European Journal Of Haematology ·Christophe Nougier, Emmanuelle Jeanpierre, Catherine Ternisien, Valérie Proulle, Nathalie Hézard, Claire Pouplard, Dominique Lasne, (unknown)	17
8	Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: Two French centres' real‐life experience 2020 ·Haemophilia ·(unknown), (unknown), Lucia Rugeri, Marc Fouassier, Anne Lienhart, Marie-C. Béné, (unknown), Catherine Ternisien, V. Chamouard, Marianne Sigaud, (unknown), Marc Trossaërt, Sandrine Meunier	1
9	Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels 2020 ·Anesthesia & Analgesia ·Elodie Boissier, Thomas Sénage, (unknown), Isabelle Gouin‐Thibault, Bertrand Rozec, Jean‐Christian Roussel, Marianne Sigaud, Catherine Ternisien, Marc Trossaërt, Marc Fouassier, Karim Lakhal	19
10	The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study 2019 ·Haemophilia ·Marc Trossaërt, J. Graveleau, (unknown), Marianne Sigaud, (unknown), A. Néel, Marc Fouassier, L. Sailler, Dominique Chauveau, Catherine Ternisien, Antoine Huart, (unknown), M. Hamidou, Marie C. Béné, Sophie Voisin	6
11	Factor VIII assays in treated hemophilia A patients 2019 ·Annales de biologie clinique ·Dominique Lasne, Claire Pouplard, Christophe Nougier, Valérie Eschwège, (unknown), Valérie Proulle, (unknown), Inès Harzallah, Sophie Voisin, Pierre Toulon, (unknown), Hubert Galinat, Claire Flaujac, Catherine Ternisien, Emmanuelle Jeanpierre	0
12	Factor IX assays in treated hemophilia B patients 2019 ·Annales de biologie clinique ·Claire Pouplard, Emmanuelle Jeanpierre, Dominique Lasne, (unknown), Valérie Eschwège, Claire Flaujac, Hubert Galinat, Inès Harzallah, Valérie Proulle, (unknown), (unknown), Catherine Ternisien, Pierre Toulon, Sophie Voisin, Christophe Nougier	1
13	A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis 2016 ·Thrombosis and Haemostasis ·Antoine Rauch, Claudine Caron, Flavien Vincent, Emmanuelle Jeanpierre, Catherine Ternisien, Pierre Boisseau, Christophe Zawadzki, Édith Fressinaud, Annie Borel‐Derlon, (unknown), Camille Paris, Cécile Lavenu‐Bombled, Agnès Veyradier, Alexandre Ung, André Vincentelli, Éric Van Belle, Peter J. Lenting, Jenny Goudemand, Sophie Susen	9
14	Validation of the first commercial ELISA for type 2N von Willebrand’s disease diagnosis 2011 ·Haemophilia ·Agnès Veyradier, Claudine Caron, Catherine Ternisien, M. Wolf, Marc Trossaërt, E Fressinaud, Jenny Goudemand	16
15	The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one‐stage clotting assay 2011 ·Haemophilia ·Claire Pouplard, Claudine Caron, M.F. Aillaud, Catherine Ternisien, Céline Desconclois, (unknown), (unknown)	22
16	Bonne pratique et valeur diagnostique de la biologie : hémostase-hématologie 2008 ·Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément ·Emmanuelle de Raucourt, Catherine Ternisien	3
17	Thrombopénie induite par l’héparine : présentation d’une observation avec complications thrombotiques graves et revue de la littérature 2002 ·Annales de Réadaptation et de Médecine Physique ·(unknown), F. Cognet, Catherine Ternisien, (unknown), (unknown), Pierre Brunel, L. Bontoux, Claire Bernat, Isabelle Richard	6
18	[A rare disease but with a very high hemorrhagic risk: acquired hemophilia A]. 2000 ·PubMed ·Vanessa C. Delisle, Catherine Ternisien, Philippe Beurrier, Marc Zandecki	2
19	Does venous microemboli detection add to the interpretation of D-dimer values following orthopedic surgery? 1999 ·Ultrasound in Medicine & Biology ·Pierre Abraham, Catherine Ternisien, Laurent Hubert, (unknown), Jean‐Louis Saumet	17
20	Interleukin 4 prevents the induction of tissue factor mRNA in human monocytes in response to LPS or PMA stimulation 1993 ·British Journal of Haematology ·(unknown), Véronique Ollivier, Catherine Ternisien, Thi Phuong Vu, (unknown), Jacques Hakim, Dominique de Prost	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact